Skip to main content

Interpreting HER2 in Breast Cancer: A full spectrum of possibilities

Course Description

Breast cancers that have human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scores of 1+ or 2+ with negative in-situ hybridization (ISH) represent around 50% of breast cancers. As research continues to explore this population of patients, which exist within the clinically negative HER2 classification, the pathologist’s approach to scoring HER2 across this complete spectrum may need to be revisited.

This comprehensive short course aims to support pathologists with distinguishing and differentiating discrete IHC scores, using a combination of short presentations and focused virtual microscopy tutorials utilizing clinical cases. Together, the three sessions will reinforce current scoring guidelines, identify opportunities to standardize testing and scoring practices, demonstrate approaches to scoring challenging cases, and showcase best practice recommendations.

To view similar clinical cases featured in this series and browse a collection of over 100 hand-selected slides, please visit– a peer-led clinical education portal supporting pathologists with the evolving need in HER2 expressing breast cancer.

The information presented represents the opinion of the presenters and is not necessarily the view of USCAP. USCAP does not endorse the products or services. The webinar is possible through a sponsorship from AstraZeneca and Daiichi Sankyo. This activity is not available for CME.

All courses will start at 11:00 AM Pacific Time.

Target Audience Practicing academic and community pathologists, and pathologists-in-training.

Learning Objectives
Upon completion of this activity, learners will able to:
  • Gain an understanding of all levels of HER2 expression across breast cancers
  • Reinforce best practices of pre-analytic, analytic, and post-analytic procedures to ensure consistent HER2 IHC results and reporting
  • Recognize tumor features that may impact HER2 IHC staining patterns and intensity

Disclosures Presenters were compensated for their time.


Marilyn Bui, MD, PhD
Senior Member and Profession in the Department of Pathology, Moffitt Cancer Center & Research Institute

Michael Feldman, MD, PhD
Professor of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine

David Hicks, MD
Tenured Professor of Pathology, University of Rochester Medical Center

Shabnam Jaffer, MD
Professor of Pathology, Molecular and Cell Based Medicine, The Icahn School of Medicine at Mount Sinai

Thaer Khoury, MD
Vice Chair of Anatomic Pathology, Chief of Breast Pathology, Roswell Park Comprehensive Cancer Center

Savitri Krishnamurthy, MD
Professor of Pathology, The University of Texas MD Anderson Cancer Center

Gary Tozbikian, MD
Associate Professor and Breast Pathology Division Director, The Ohio State University Wexner Medical Center

Shi Wei, MD, PhD
Professor of Pathology and Laboratory Medicine, The Barbara F. Atkinson Endowed Professor, Director of Translational Research, University of Kansas Medical Center

Hannah Wen, MD, PhD
Director, Breast Pathology Fellowship, Memorial Sloan Kettering Cancer Center

Privacy Notice The webinar is possible through a sponsorship from AstraZeneca and Daiichi Sankyo. This content is not available for continuing medical education. If you continue to register, you are acknowledging that your information will be shared with the company, including your name, degrees, institution, NPI number, mailing address, email address, and phone number. USCAP has no control over the use of this information and encourages you to review their privacy policies. 
Daiichi Sankyo

This course is free.
Please use the code  HER2Know at checkout.